| Outcome Measures: |
Primary: The improvement in histologic features of NAFLD, 48 weeks | Secondary: Change from baseline in liver enzymes, 48 weeks|Change from baseline in body composition, 48 weeks|Change from baseline in fasting plasma glucose level and glucose metabolism assessed with arginine tolerance test, 48 weeks|Changes from baseline in organ-specific insulin sensitivity and glucagon response during a euglycemic hyperinsulinemic clamp study, 48 weeks|Change from baseline in lipid profile, 48 weeks|Change from baseline in renal function and electrolyte balances, 48 weeks|Change from baseline in oxidative stress, 48 weeks|Change from baseline in cytokine (TNF-alpha, leptin, adiponectin) levels, 48 weeks|Change from baseline in hepatokine (Selenoprotein P, LECT2) levels, 48 weeks|Change from baseline in organ-specific fat accumulation, 48 weeks|Change from baseline in oxidative and non-oxidative glucose disposal, 48 weeks|Change from baseline in respiratory quotients, 48 weeks|Change from baseline in energy expenditure, 48 weeks|Change from baseline in autonomic nerve function., 48 weeks|Changes from baseline in minerals and bone metabolism, 48 weeks|Changes from baseline in endothelial functions, 48 weeks|Changes from baseline in fatty acids profiles, 48 weeks|Factors associated with the changes in autonomic nerve function, organ-specific fat accumulation, and glucagon response., 48 weeks|Changes from baseline in gene expression profiles in the liver and blood cells, 48 weeks|Changes from baseline in microRNAs and exosome contents, 48 weeks|Epigenomic changes from baseline in genes of the liver and blood cells, 48 weeks
|
